Introduction Tumor molecular profiling by next-generation sequencing (NGS) aims to use information on somatic tumor-specific variants to direct cancer treatment. A significant challenge in tumor molecular profiling is identifying tumor-specific variants in the presence of germline variants which are also identified during tumor testing. The majority of germline variants are benign changes not contributing to the cancer occurrence, although

Join for free to read